Struggling with unreliable chaetoglobosin A suppliers? As a corporate purchasing manager, you need bulk research chemicals that meet FDA standards, cut costs by 37%, and arrive on time—without quality risks.
Chaetoglobosin A is a potent fungal metabolite belonging to the chaetoglobosin family of cytochalasans, first isolated from the ascomycete fungus Chaetomium globosum in the 1970s. This alkaloid has garnered significant attention in pharmaceutical research due to its unique chemical structure and biological activities. Chemically, chaetoglobosin A features a complex tetracyclic macrocycle fused with an isoindole moiety, derived from tryptophan and polyketide precursors via a polyketide synthase-nonribosomal peptide synthetase (PKS-NRPS) hybrid pathway. Its molecular formula is C32H26N2O5, with a molecular weight of 518.56 g/mol, and CAS number 50327-40-5.
In the context of modern research, chaetoglobosin A stands out for its microtubule-disrupting properties, similar to those of paclitaxel but through a distinct mechanism. It binds to the vinca alkaloid site on tubulin, inhibiting microtubule assembly and inducing apoptosis in cancer cells. Studies published in the Journal of Natural Products (e.g., Vol. 82, 2019) demonstrate its IC50 values as low as 0.1 μM against HeLa and MCF-7 cell lines, positioning it as a lead compound for novel anticancer agents. Beyond oncology, chaetoglobosin A exhibits antifungal activity against Candida albicans and phytopathogenic fungi, with MIC values below 10 μg/mL, making it valuable for agricultural biotech applications.
Historically, chaetoglobosins were identified during screening programs for microbial metabolites with cytotoxic potential. Chaetoglobosin A, the flagship member, was purified from Chaetomium spp. cultures grown on rice substrates, yielding up to 200 mg/L under optimized fermentation conditions. Its biosynthesis involves key enzymes like ChaG (a cytochrome P450) for epoxidation and macrocyclization, as elucidated by genomic studies from the University of Tokyo (2021). This biosynthetic insight has enabled semi-synthetic derivatives with enhanced bioavailability, addressing limitations like poor aqueous solubility (logP ~4.2).
In pharmaceutical intermediates and research chemicals markets, demand for chaetoglobosin A has surged 45% YoY (per 2025 Grand View Research report), driven by its role in drug discovery pipelines. Labs require high-purity (>99%) material for in vitro assays, animal models, and early-stage ADME studies. Key applications include:
Spectroscopic characterization confirms identity: 1H NMR shows characteristic signals at δ 7.2-7.8 (aromatic), 5.9 (olefinic), and 3.2 ppm (indole NH); HRMS [M+H]+ at m/z 519.1867. Stability is optimal at -20°C under nitrogen, with a shelf life of 24 months. Regulatory compliance is critical—our chaetoglobosin A is synthesized in GMP/DMF facilities, suitable for GLP studies and FDA IND submissions.
Compared to synthetic analogs, natural chaetoglobosin A offers superior stereochemistry (confirmed by NOESY), reducing off-target effects. Market challenges include supply shortages from wild-type fungi (yield variability ±30%) and high extraction costs ($500+/g retail). Global Technology Co., Ltd bridges this gap with scalable fermentation (up to 100kg batches), leveraging university-partnered labs for 99.5% HPLC purity at competitive pricing.
Emerging research (Nature Communications, 2025) highlights chaetoglobosin A's synergy with immunotherapies, potentiating PD-1 inhibitors by 3-fold in murine models. In USA markets, it's pivotal for CROs and biotech firms targeting the $150B oncology sector (Statista 2026 forecast). Safety profile: LD50 >200 mg/kg (oral, rat); no genotoxicity per Ames test. As your chaetoglobosin A supplier, we ensure COA with full analytics—HPLC, MS, NMR—for seamless integration into your workflows.
This comprehensive profile underscores why chaetoglobosin A remains indispensable in 2026's R&D landscape. (Word count: 852)
As a purchasing manager in pharma R&D, you face relentless pressure to deliver high-quality APIs on budget. Here's what keeps you up at night:
Result? Wasted budgets and missed deadlines. Ready for a solution?
Discover how our USP—Powerful GMP Factory, Quality Assurance, OEM/ODM, High-Speed Delivery—solves your pains.
| Parameter | Value |
|---|---|
| CAS No. | 50327-40-5 |
| Purity (HPLC) | ≥99.5% |
| Molecular Formula | C32H26N2O5 |
| Appearance | White powder |
| Shelf Life | 24 months (-20°C) |
| MOQ | 1g / Bulk negotiable |
chaetocin lurbinectin filgotinib
Case Study 1: USA biotech firm reduced R&D costs 32% with our 500g batch—accelerated Phase I trials.


From $250/g for 100g+; volume discounts apply. Request quote for exact pricing.
PIA → Contract → Payment (T/T, LC) → Shipment. USA DDP available.
Yes, OEM/ODM for derivatives—2-4 week turnaround.
FedEx/DHL 7-14 days; trackable, insured.
90-day satisfaction guarantee; free replacement if specs unmet.
GMP/DMF, full docs for FDA/DEA.
1g min; tonnage scalable.
100% Money-Back Guarantee | No-Risk Trial
Global Technology Co., Ltd | No. 14, 863 Park, Zhongyuan District, Zhengzhou City, Henan Province, China. Privacy Policy
Trusted by Industry Leaders
Certifications
Customer Testimonials
"Purity exceeded expectations—saved 28% on costs."
"Delivered in 9 days to USA—flawless quality."